Tired of pitfalls in synthesizing CAR mRNA yourself?

Struggling with tLNP antibody conjugation?

Waiting for materials slowing down your experiments?

To help researchers more conveniently access validated mRNA and mRNA-tLNP, Enorna officially launches its first batch of ready-to-use mRNA & tLNP off-the-shelf products, providing customers with standardized, high-quality solutions.

• Off-the-Shelf Products, Meeting Diverse Application Needs

The initial product lineup includes reporter gene mRNA, CAR mRNA for cell therapy, and targeted lipid nanoparticles (tLNP), precisely matching different research directions.

Highlights of the Product Batch:

• Reporter Gene mRNA: Includes eGFP mRNA and Fluc mRNA, gold standards for validation studies, providing a stable and reliable control system for mRNA research and accelerating experimental validation.
• CAR mRNA: Features both single-target CD19 CAR mRNA and dual-target CD19 & CD20 CAR mRNA, ready for direct use in various mRNA-based cell therapy or in vivo CAR research projects, eliminating the need for custom design.
• Targeted LNP Product for Cytotoxic T Cells: eGFP mRNA tLNP product designed to target CD8+ T cells, providing an efficient and precise targeted delivery research tool for in vivo CAR-T studies.
• Why Choose Enorna mRNA & tLNP Off-the-Shelf Products?

Manufactured using industrial-grade preparation and purification processes and subjected to stringent quality control (QC) protocols to ensure each batch meets high-quality standards.

• Excellent Performance Data
  • High Quality: Features 5' Cap1 capping efficiency ≥98%, 3' poly(A) tail length ≥100 nts, incorporation of m1Ψ modification to reduce immunogenicity and enhance expression, and mRNA integrity up to 98%.
  • Comprehensive QC: mRNA products undergo 7 key QC tests; tLNP products include 9 final product tests + 3 intermediate mRNA QC controls. Each batch comes with a detailed QC report.
  • Suitable for Immune Cell Research: Processes and purification steps are optimized to control endotoxin levels < 10 EU/mg and dsRNA ≤ 0.1%, minimizing non-specific immune responses in immune cells.
• Rapid Delivery
  • Ready-to-Ship: Orders can ship as fast as the same day, with standard delivery ensuring arrival within 3 business days (For China mainland shipping).
  • End-to-End Cold Chain: Products are shipped with ample dry ice, maintaining ultra-low temperatures throughout transit to ensure product activity.

Case Study 1: High-Level Expression of eGFP mRNA in Cells

To validate the expression efficiency of Enorna's off-the-shelf mRNA products, we delivered our eGFP mRNA (m1Ψ) into 293T cells via transient transfection. Results showed that over 95% of cells were eGFP-positive 24 hours post-transfection. Our off-the-shelf products provide researchers with a high-quality, ready-to-use standard experimental control, ensuring reliable and reproducible results.

Expression of Enorna eGFP mRNA in 293T cells at 24h

Case Study 2: CD8 Antibody Conjugation Efficiency of eGFP mRNA CD8+ tLNP Reaches ~90%

Using nanoflow cytometry to detect the positive rate of CD8 antibodies on the surface of eGFP mRNA CD8+ tLNP nanoparticles, we currently achieve approximately 90% antibody-positive rate. This ensures good CD8 targeting and delivery efficiency, providing researchers conducting in vivo CAR/targeted delivery studies with a high-quality standard experimental control to ensure reliability and smooth progress in their research.

Detection of CD8 Antibody Positive Rate for eGFP mRNA CD8+ tLNP via Nanoflow Cytometry